According to the study published in the Journal of Cancer Biology and Therapy, 2013, the controversial discovery of the 20th century by Otto Warburg led to study of metabolic activity in cancerous tissue, which increases the amount of production of lactate from glucose by tenfold under aerobic condition. This has revealed that heterogeneity is developed at cellular level leading to proliferation of cancerous cells due to increased metabolism rate. Cancer metabolism is based on the principle of cancer cells, which alter the metabolism of glucose and glutamine for the synthesis of lipids, nucleotides, fatty acids, and proteins that helps to proliferate cancer cells. It results in inhibition of various metabolic pathways, such as the citric acid cycle, glucose, mitochondrial respiration, and glutamine utilization. Limited options of cancer metabolism targeting therapies are expected provide potential opportunities for development of novel cancer metabolism-based therapeutics in the near future.
Global Cancer Metabolism Based Therapeutics Market Taxonomy
On the basis of drug and indication, cancer metabolism-based therapeutics market segmented into two categories
By Drug –
By Indication –
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes (MDS)
- Metastatic Renal Cell Carcinoma
Targeting cancer metabolism condition represents a potential opportunity to develop novel drugs to treat multiple cancer types, which is expected to boost the growth of cancer metabolism-based therapeutics market
Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound – Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in near future. Therefore, offering orphan drug to the cancer patients would help to gain more value and share for cancer metabolism based therapeutics market.
Celgene Corporation and Agios Pharmaceutical announced that the Food and Drug Administration (FDA) approved New Drug Application (NDA) for enasidenib – oral form, in August 2017. The FDA granted the NDA, as a priority review for cancer metabolism drug. Enasidenib is a first-in-class drug, which is expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation.
For In depth Information Get Sample Copy of this Report at: https://www.coherentmarketinsights.com/insight/request-sample/961
Calithera Biosciences, Inc. announced novel cancer therapeutic drug named CB–839 in 2017. The FDA granted CB-839 as a Fast Track designation drug with the combination of everolimus for the treatment of metastatic renal cell carcinoma. CB-839 is being evaluated in clinical trials phase I and II for the treatment of solid tumors non-small cell lung cancer, renal cell carcinoma, melanoma, and triple negative breast cancer.